News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer
Jul 25, 2024, 20:48

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

Dana-Farber’s Breast Oncology Center shared on X:

“New in JCO Oncology Practice:

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).

Full Text here.”

Source: Dana-Farber’s Breast Oncology Center/X

Breast Cancer

Authors: Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Victoria Attaya, Cari Ryding, Ibrahim Abbass, Anita Fung, Jesse Sussell, Patricia Cortazar, Caroline Harvey, Denise Leth, Meredith Faggen, Natalie Sinclair, Jeanna Walsh, Nadine Tung, Sarah Sinclair, Steve Lo, Denise Yardley, Vicente Valero, Jane Meisel, Tarah J Ballinger, Sylvia Adams, Lisa A Carey, Julia K Rauch, Vandana G Abramson, Nicole O Williams, Wendy Y Chen, Jose P Leone, Susan T Schumer, Nabihah Tayob, Sara M Tolaney

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)

Anita Fung Anna Mae Frey Breast Cancer cancer Cari Ryding Caroline Harvey Dana-Farber’s Breast Oncology Center Denise Leth Denise Yardley Emily L Chen Here are the names with the numbers removed: Adrienne G Waks Ibrahim Abbass Jane Meisel JCO Oncology Practice Jeanna Walsh Jesse Sussell Jose P Leone Julia K Rauch Kenneth Almeida Lisa A. Carey Meredith Faggen Nabihah Tayob Nadine Tung Natalie Sinclair Nicole O Williams Noah Graham OncoDaily Oncology Patricia Cortazar pertuzumab Sara M. Tolaney Sarah Sinclair Steve Lo Susan T Schumer Sylvia Adams Tarah J Ballinger trastuzumab Vandana G Abramson Vicente Valero Victoria Attaya Wendy Y. Chen
Special Coverage
Blog
Jan 19, 2025, 15:36
Paolo Tarantino: How do you plan to use Datopotamab Deruxtecan for HR+/HER2- MBC?
Science
Jan 19, 2025, 15:26
Andrea Necchi: Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with mCRPC
Insight
Jan 19, 2025, 15:23
Aleix Prat: Excited to share the results of the SOLTI-ELIPSE trial
Blog
Jan 19, 2025, 15:20
Danish Melanoma Lifetime Achievement Award to Lars Bastholt - Danish Metastatic Melanoma Database
Blog
Jan 19, 2025, 15:16
Caroline N. Smith: Hiring for an Assistant Director, Foundation and Scientific Partnerships at the V Foundation for Cancer Research
Blog
Jan 19, 2025, 15:12
Narjust Florez on the challenges and overwhelming sense of not belonging as a Latina in Medicine
Blog
Jan 19, 2025, 15:11
Monica Bertagnolli: It has been a privilege to serve as Director of NIH under President Joe Biden
Blog
Jan 19, 2025, 15:08
Cathy Eng: Speaking about the rising incidence of early-onset colorectal cancer at Tamron Hall Show
Blog
Jan 19, 2025, 15:04
Pam Mangat-Dhaliwal: How ASCO is putting its commitment to patient advocacy into action
Blog
Jan 19, 2025, 14:53
Dégi László Csaba: Thrilled to announce that I’ll be in Davos for the World Economic Forum
Insight
Jan 19, 2025, 14:52
Aleix Prat: The Katherine phase III updated results are out
Insight
Jan 19, 2025, 14:19
Gustavo Viani: Breaking Barriers in Global Oncology